Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
about
Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeuticsHuman phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progressionReaders of histone methylarginine marks.Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerValidation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.Deciphering the function of non-coding RNAs in prostate cancer.Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancerHuman PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.Androgen receptor profiling predicts prostate cancer outcome.Domain retention in transcription factor fusion genes and its biological and clinical implications: a pan-cancer study.Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.
P2860
Q27323950-6D8ED388-4BD5-4911-BFC8-378D532FCC39Q28078594-709755EA-3A45-47ED-89F5-D9DCA65C6FEFQ28269917-FF42A145-E230-46DA-A048-6C993C8DFB08Q30359633-C776710D-31BC-4EF3-B4B0-8516EF4D398CQ30938412-0A6D3BD9-D015-4209-813E-6F25AB216FE4Q36022437-728646C2-3346-42A7-8D4B-55D91F04334AQ36025180-D864496D-AF83-48D9-8E33-D2FD509D4788Q36035812-3D5FD688-AD70-4413-827A-4EC2E55AE460Q36043833-266020C2-8DEC-4567-9CC1-52CB1D51CFF1Q37269294-61AC965A-D533-43E2-BE94-657147680594Q38734374-35F213BE-84BF-4B8A-98B9-D0CC3909AE2AQ38766041-4C017266-6AF5-455A-94B7-E6F5DB867D95Q38843392-9720181D-09B9-4171-857F-676F2C2683F2Q38909020-5C5556B6-71A2-4409-A294-1D805828DBCDQ39341456-C9748971-A2D2-4D07-9DEC-A4237D6C96AEQ39909790-C5789444-2AC0-4F09-99EE-B8474A1CF4A6Q40493333-858565B8-61DC-4409-84D9-9F215158EDF6Q47164118-9C0A1CAC-7CB7-4754-9747-23D7378ABC2DQ55398136-DDA35AED-F59D-4C42-A8E2-EAFC64D8B848
P2860
Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
@en
type
label
Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
@en
prefLabel
Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
@en
P2093
P2860
P356
P1476
Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
@en
P2093
Angelique J C Ziel-van der Made
Carola V de Vos
Geert J L H van Leenders
Guido Jenster
Hanneke Korsten
Jan Trapman
Joost L Boormans
P2860
P304
P356
10.1002/IJC.28025
P577
2013-02-12T00:00:00Z